Skip to main content

23andMe Holding Co. (ME)

NASDAQ: ME · IEX Real-Time Price · USD
8.96 0.44 (5.16%)
Sep 22, 2021 1:28 PM EDT - Market open
Market Cap3.50B
Revenue (ttm)303.16M
Net Income (ttm)-225.63M
Shares Out93.03M
EPS (ttm)-3.06
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close8.52
Day's Range8.46 - 9.30
52-Week Range7.01 - 18.16
Price Target13.00 (+45.1%)
Est. Earnings DateNov 12, 2021

About ME

23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a ...

IndustryDiagnostics & Research
Stock ExchangeNASDAQ
Ticker SymbolME
Full Company Profile

Financial Performance

In 2020, 23andMe's revenue was $243.92 million, a decrease of -20.15% compared to the previous year's $305.46 million. Losses were -$183.62 million, -26.81% less than in 2019.

Financial Statements


‘Absolutely' a future where everyone's DNA sequenced at birth: 23andMe CEO

23andMe Co-Founder & CEO Anne Wojcicki joins 'Influencers with Andy Serwer' to discuss the future of personal genomics.  Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: h...

3 hours ago - Yahoo Finance

Here's Why I Bought This Recent Genetics IPO

Despite losing millions right now, this company could have massive long-term growth potential.

7 hours ago - The Motley Fool

7 SPACs to Buy That Are Better Than Bill Ackman's Pershing Square Tontine

The billionaire's blank-check company proved to be a bust, but these seven other SPACs still have a shot at becoming long-term winners. The post 7 SPACs to Buy That Are Better Than Bill Ackman's Pershin...

1 week ago - InvestorPlace

3 Stocks I Bought That Could Produce 10X Returns

These aren't exactly low-risk stocks, but the long-term potential could be enormous.

Other symbols:MELIOPAD
1 week ago - The Motley Fool

This Biotech Company Could Offer Nearly Unlimited Optionality

Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions.

Other symbols:GSK
3 weeks ago - The Motley Fool

2 SPACs That Look Like Bargains After Post-Earnings Drops

Many recent SPAC IPOs have been hammered, and these two could be worth a closer look.

Other symbols:SOFI
1 month ago - The Motley Fool

5 Blazing Stocks to Buy Trading Under $10 With Massive Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

1 month ago - 24/7 Wall Street

ME Stock: The Credit Suisse Call Giving 23andMe a Boost Today

23andMe (ME) stock is rising higher on Tuesday after Credit Suisse weighed in on the personal genomics and biotechnology company. The post ME Stock: The Credit Suisse Call Giving 23andMe a Boost Today a...

1 month ago - InvestorPlace

Why 23andMe Stock Soared Today

It's no great secret why Credit Suisse likes 23andMe.

1 month ago - The Motley Fool

Why 23andMe's Stock Is Trading Higher Tuesday

23andMe Holding Co. (NASDAQ:ME) shares are trading higher by 6.6% at $7.77 Tuesday morning after Credit Suisse initiated coverage on the stock with an Outperform rating and announced a $13 price target....

1 month ago - Benzinga

23andMe Reports FY2022 First Quarter Financial Results

First quarter revenue up 23% over prior year Strong cash balance of $770 million Continuing to advance therapeutics portfolio to drive future revenue growth

1 month ago - GlobeNewsWire

Here's the Biggest Predictor of a SPAC's Success

There is one factor that is closely correlated with the returns a SPAC produces for investors.

2 months ago - The Motley Fool

Why Aren't More Companies Using SPACs for Their IPOs?

The SPAC boom has died down, but IPOs have not.

Other symbols:PAYOPLTR
2 months ago - The Motley Fool

Got $2,500? Check Out These 2 Biotech 2.0 Stocks

They're poised to disrupt the drug development process.

Other symbols:RXRX
2 months ago - The Motley Fool

Is 23andMe a Buy at $11?

Yes, but it'll take a while to grow with gusto.

2 months ago - The Motley Fool

2 Growth Stocks to Put on Your Radar

Here are two stocks our experts are keeping their eye on right now.

Other symbols:ADBE
2 months ago - The Motley Fool

Can You Count on 23andMe Stock?

This innovative consumer genetic testing company is more than meets the eye.

2 months ago - The Motley Fool

Industry Leaders Join 23andMe Board of Directors

Dr. Valerie Montgomery Rice and Peter Taylor Join 23andMe's Board as the Company Sets to Accelerate Personalized Healthcare Based on Human Genetics Dr. Valerie Montgomery Rice and Peter Taylor Join 23an...

3 months ago - GlobeNewsWire

23andMe CEO on public debut, future of genetic testing

This segment originally aired on June 17, 2021. DNA testing company 23andMe started trading on Thursday, under the ticker ‘ME'.

3 months ago - Yahoo Finance

ME Stock: 14 Things for Investors to Know About 23andMe Following Its Nasdaq Debut

23andMe (ME) stock is on the move Friday after the genetics company made its public debut on the Nasdaq Exchange yesterday. The post ME Stock: 14 Things for Investors to Know About 23andMe Following Its...

3 months ago - InvestorPlace

23andMe CEO on Trading Debut, GSK Deal, Branson SPAC

Jun.17 -- 23andMe Inc. CEO Anne Wojcicki discusses the DNA-testing company's NASDAQ trading debut, a collaboration on drug development with GlaxoSmithKline Plc, and the choice to go public through a mer...

Other symbols:GSK
3 months ago - Bloomberg Technology

DNA Testing Company 23andMe Makes Nasdaq Debut

Consumer genetic testing company 23andMe has made its Nasdaq debut at about $11 a share. CEO Anne Wojcicki joined Cheddar to talk about taking the company public through a SPAC merger.

3 months ago - Cheddar

23andMe jumps on stock market debut, as privacy concerns about genetic testing abound

The company is the latest to go public via a SPAC deal. 23andMe, the direct-to-consumer genetic testing company headquartered in Sunnyvale, California, popped on its stock market debut Thursday.

3 months ago - Fast Company

Why 23andMe Stock Just Jumped 10%

Congratulations, 23andMe. You're a public stock now!

3 months ago - The Motley Fool

23andMe Successfully Closes its Business Combination with VG Acquisition Corp.

Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17 Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17

3 months ago - GlobeNewsWire